

Cover image: Amyloid A deposits in colon of patient with rheumatoid arthritis before and after 3 months of tocilizumab treatment. See p1236.

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum

Hans Bijlsma

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Iain McInnes

Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: ard@bmj.com

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 6.411

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2009 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK

Annals of the Rheumatic Diseases (USPS No: 002-152) is published monthly by BMJ Publishing Group and distributed in the USA by Pitney Bowes International Mailing Services Inc as mailing agent. Periodicals postage paid at Kearny, NJ, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, PB International Mailing Services Inc, 500 US Hwy 46, Clifton, NJ 07011, USA.

Editorial

1081 Methotrexate: the gold standard without standardisation

J Kay, R Westhovens

Review

1083 Erectile dysfunction in systemic sclerosis

U A Walker, A Tyndall, R Ruszat

Recommendation

1086 Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

K Visser, W Katchamart, E Loza, J A Martinez-Lopez, C Salliot, J Trudeau, C Bombardier, L Carmona, D van der Heijde, J W J Bijlsma, D T Boumpas, H Canhao, C J Edwards, V Hamuryudan, T K Kvien, B F Leeb, E M Martín-Mola, H. Mielants, U Müller-Ladner, G Murphy, M Østergaard, I A Pereira, C Ramos-Remus, G Valentini, J Zochling, M Dougados

Clinical and epidemiological research

1094 Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

K Visser, D van der Heijde

1100 Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

C Salliot, D van der Heijde

1105 Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis

W Katchamart, J Trudeau, V Phumethum, C Bombardier

1113 Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy

D van der Heijde, G Burmester, J Melo-Gomes, C Codreanu, E Martin Mola, R Pedersen, D Robertson, D Chang, A Koenig, B Freundlich for the Etanercept Study Investigators

1119 Dose-related patterns of glucocorticoid-induced side effects

D Huscher, K Thiele, E Gromnica-Ihle, G Hein, W Demary, R Dreher, A Zink, F Buttgerit

1125 Deoxyspergualin in relapsing and refractory Wegener's granulomatosis

O Flossmann, B Baslund, A Bruchfeld, J W Cohen Tervaert, C Hall, P Heinzel, B Hellmich, R A Luqmani, K Nemoto, V Tesar, D R W Jayne

1131 Cardiovascular morbidity in psoriatic arthritis

D D Gladman, M Ang, L Su, B D M Tom, C T Schentag, V T Farewell

1136 The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

J P Leombruno, T R Einarson, E C Keystone

1146 Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study

B Combe, C Codreanu, U Fiocco, M Gaubitz, P P Geusens, T K Kvien, K Pavelka, P N Sambrook, J S Smolen, R Khandker, A Singh, J Wajdula, S Fatenejad, for the Etanercept European Investigators Network

1153 Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis

S M van der Kooij, S le Cessie, Y P M Goekoop-Ruiterman, J K de Vries-Bouwstra, D van Zeben, P J S M Kerstens, J M W Hazes, D van Schaardenburg, F C Breedveld, B A C Dijkmans, C F Allaart

1159 Perinatal characteristics, early life infections and later risk of rheumatoid arthritis and juvenile idiopathic arthritis

C Carlens, L Jacobsson, L Brandt, S Cnattingius, O Stephansson, J Askeling

1165 Reproductive history, hormonal factors and the incidence of hip and knee replacement for osteoarthritis in middle-aged women

B Liu, A Balkwill, C Cooper, A Roddam, A Brown, V Beral, on behalf of the Million Women Study Collaborators

1171 Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study

M Hoff, T K Kvien, J Kälvesten, A Elden, G Haugeberg

MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>




COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



When you have finished with this please recycle it

- 1177** Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
T Bongartz, F C Warren, D Mines, E L Matteson, K R Abrams, A J Sutton
- 1184** Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis
F Banal, M Dougados, C Combescure, L Gossec
- 1192** Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences
S Bernatsky, L Joseph, C A Pineau, P Bélisle, J F Boivin, D Banerjee, A E Clarke
- 1197** Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis
H Marotte, E Gineyts, P Miossec, P D Delmas
-
- Basic and translational research**
- 1201** Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance
E Kis, T Nagy, M Jani, É Molnár, J Jánossy, O Ujhellyi, K Németh, K Herédi-Szabó, P Krajcsi
- 1208** Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity
S Candon, J E Gottenberg, D Bengoufa, L Chatenoud, X Mariette
- 1213** The cyclic GMP-dependent protein kinase II gene associates with gout disease: identified by genome-wide analysis and case-control study
S-J Chang, M-H Tsai, Y-C Ko, P-C Tsai, C-J Chen, H-M Lai
- 1220** Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

M H Buch, D L Boyle, S Rosengren, B Saleem, R J Reece, L A Rhodes, A Radjenovic, A English, H Tang, G Vratsanos, P O'Connor, G S Firestein, P Emery
-
- Letters**
- 1228** When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
F H M Prince, M Twilt, S C M Simon, M A J van Rossum, W Armbrust, E P A H Hoppenreijns, S Kamphuis, M van Santen-Hoeufft, Y Koopman-Keemink, N M Wulffraat, R ten Cate, L W A van Suijlekom-Smit
- 1230** *IL23R* and *IL12B* genes: susceptibility analysis in rheumatoid arthritis
J Varade, J Ramón Lamas, L Rodríguez, M Fernández-Arquero, E Loza-Santamaría, J Á Jover, E G de la Concha, B Fernández-Gutierrez, E Urcelay, A Martínez
- 1232** Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis
M J L Peters, M T Nurmohamed, I C van Eijck, C J N Verkleij, P F Marx
- 1233** Bilateral parotid gland involvement in Wegener granulomatosis
A K Saha, S Rachapalli, S Steer, P Gordon
- 1234** Different effects of local cryogel and cold air physical therapy in wrist rheumatoid arthritis visualised by power Doppler ultrasound
K Albrecht, C Albert, U Lange, U Müller-Ladner, J Strunk
- 1235** Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment
S Nishida, K Hagihara, Y Shima, M Kawai, Y Kuwahara, J Arimitsu, T Hirano, M Narazaki, A Ogata, K Yoshizaki, I Kawase, T Kishimoto, T Tanaka
-
- Miscellaneous**
- 1170** Retraction

Take the pain out of research every month

Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 6.411, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for **just £227 a year** (€306, \$443). Too much paper on your desk already? An online subscription is **just £106** (€143, \$207).

Visit group.bmj.com/group/subs-sales - your subscription to this first class journal is just a few clicks away.

ard.bmj.com

BMJ Journals

